TY - JOUR
T1 - Dose-response for assessing the cancer risk of inorganic arsenic in drinking water
T2 - the scientific basis for use of a threshold approach
AU - Tsuji, Joyce S.
AU - Chang, Ellen T.
AU - Gentry, P. Robinan
AU - Clewell, Harvey J.
AU - Boffetta, Paolo
AU - Cohen, Samuel M.
N1 - Funding Information:
J.S. Tsuji has provided scientific consultation to the Arsenic Science Task Force (ASTF), the Wood Preservatives Science Council (WPSC), and the Electric Power Research Institute (EPRI) regarding arsenic dose-response issues, including providing public comments on USEPA Integrated Risk and Information System (IRIS) assessments for arsenic. The ASTF represents trade associations of industries, manufacturers, and agricultural producers with interests in the scientific and regulatory developments on arsenic. WPSC is a trade organization funded by manufacturers of wood preservative chemicals including those containing arsenic. EPRI is a nonprofit organization that conducts research, development, and demonstration projects on scientific topics of interest to electric utilities. Its members are mostly electric utilities, and also include businesses, government agencies, regulators, and public and private entities. Some of J.S. Tsuji and E.T. Chang’s published papers on arsenic were partially funded by the ASTF and EPRI. Some of J.S. Tsuji’s publications were also partially funded by Rio Tinto (a mining company), the American Chemistry Council (specifically, companies within the anti-microbial sector of this chemical trade organization that funds research on health, safety, and the environment), or ILSI North America Technical Committee on Food and Chemical Safety. ILSI is a nonprofit foundation (funded by member food companies) focused on scientific issues related to nutritional quality and safety of the food supply. The arsenic biomonitoring study in New York published by J.S. Tsuji was funded by FMC Corporation (a former manufacturer of arsenic-based pesticides); FMC had no role in providing comments on the reporting of the biomonitoring study results or in funding its publication. J.S. Tsuji has also provided public comments on arsenic exposure and health risks from treated wood on behalf of the above parties, and scientific consultation to a number of mining companies, the Tennessee Valley Authority, and the USEPA for conducting health risk assessments of arsenic at contaminated sites, and in guiding cleanup of sites. J.S. Tsuji has also provided expert testimony and E.T. Chang has provided scientific consultation on behalf of both defendants and plaintiffs on arsenic exposure and health risk in legal cases.
Funding Information:
The work involved with this evaluation and the development of this manuscript was supported by a contract from the Texas Commission on Environmental Quality (TCEQ). No other sources of support were used for this project. TCEQ reviewed the manuscript and suggested minor edits, but the content is that of the authors. We gratefully acknowledge Lora Arnold, Jeanne Bradford, and Betty Dowd for their assistance with the preparation of this manuscript. We are very appreciative of the many helpful comments and suggestions provided by the peer reviewers that improved the manuscript.
Funding Information:
The research of P. Boffetta has been supported by the US National Cancer Institute and the US Centers for Disease Control and Prevention. He has received financial support from the ASTF for analysis of arsenic exposure and cancer risk. He received a subcontract from Ramboll US Corp. for his role in the preparation of this manuscript.
Funding Information:
The research of S.M. Cohen has been supported by the US National Cancer Institute, ILSI North America Technical Committee on Food and Chemical Safety, EPRI, ASTF, the Organic Arsenical Products Task Force (OAPTF) (trade organization of companies producing methylated arsenicals for pesticide use), USEPA, Alberta Health (from the Canadian Province of Alberta), Alberta Innovates (from the Canadian Province of Alberta), Canada Research Chair's Program, Canadian Institute of Health Research, and Natural Sciences and Engineering Research Council of Canada. S.M. Cohen has also provided public comments on USEPA IRIS assessment for arsenic.
Publisher Copyright:
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/1/2
Y1 - 2019/1/2
N2 - The biologic effects of inorganic arsenic predominantly involve reaction of the trivalent forms with sulfhydryl groups in critical proteins in target cells, potentially leading to various toxicologic events including cancer. This mode of action is a threshold process, requiring sufficient concentrations of trivalent arsenic to disrupt normal cellular function. Nevertheless, cancer risk assessments for inorganic arsenic have traditionally utilized various dose-response models that extrapolate risks from high doses assuming low-dose linearity without a threshold. We present here an approach for a cancer risk assessment for inorganic arsenic in drinking water that involves considerations of this threshold process. Extensive investigations in mode of action analysis, in vitro studies (>0.1 µM), and in animal studies (>2 mg/L in drinking water or 2 mg/kg of diet), collectively indicate a threshold basis for inorganic arsenic-related cancers. These studies support a threshold for the effects of arsenic in humans of 50–100 µg/L in drinking water (about 65 µg/L). We then evaluate the epidemiology of cancers of the urinary bladder, lung, and skin and non-cancer skin changes for consistency with this calculated value, focusing on studies involving low-level exposures to inorganic arsenic primarily in drinking water (approximately <150 µg/L). Based on the relevant epidemiological studies with individual-level data, a threshold level for inorganic arsenic in the drinking water for these cancers is estimated to be around 100 µg/L, with strong evidence that it is between 50 and 150 µg/L, consistent with the value calculated based on mechanistic, in vitro and in vivo investigations. This evaluation provides an alternative mode of action-based approach for assessing health-protective levels for oral arsenic exposure based on the collective in vitro, in vivo, and human evidence rather than the use of a linear low-dose extrapolation based on default assumptions and theories.
AB - The biologic effects of inorganic arsenic predominantly involve reaction of the trivalent forms with sulfhydryl groups in critical proteins in target cells, potentially leading to various toxicologic events including cancer. This mode of action is a threshold process, requiring sufficient concentrations of trivalent arsenic to disrupt normal cellular function. Nevertheless, cancer risk assessments for inorganic arsenic have traditionally utilized various dose-response models that extrapolate risks from high doses assuming low-dose linearity without a threshold. We present here an approach for a cancer risk assessment for inorganic arsenic in drinking water that involves considerations of this threshold process. Extensive investigations in mode of action analysis, in vitro studies (>0.1 µM), and in animal studies (>2 mg/L in drinking water or 2 mg/kg of diet), collectively indicate a threshold basis for inorganic arsenic-related cancers. These studies support a threshold for the effects of arsenic in humans of 50–100 µg/L in drinking water (about 65 µg/L). We then evaluate the epidemiology of cancers of the urinary bladder, lung, and skin and non-cancer skin changes for consistency with this calculated value, focusing on studies involving low-level exposures to inorganic arsenic primarily in drinking water (approximately <150 µg/L). Based on the relevant epidemiological studies with individual-level data, a threshold level for inorganic arsenic in the drinking water for these cancers is estimated to be around 100 µg/L, with strong evidence that it is between 50 and 150 µg/L, consistent with the value calculated based on mechanistic, in vitro and in vivo investigations. This evaluation provides an alternative mode of action-based approach for assessing health-protective levels for oral arsenic exposure based on the collective in vitro, in vivo, and human evidence rather than the use of a linear low-dose extrapolation based on default assumptions and theories.
KW - Arsenic
KW - animal toxicology
KW - cancer risk assessment
KW - epidemiology
KW - in vitro
KW - threshold
UR - http://www.scopus.com/inward/record.url?scp=85072059129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072059129&partnerID=8YFLogxK
U2 - 10.1080/10408444.2019.1573804
DO - 10.1080/10408444.2019.1573804
M3 - Review article
C2 - 30932726
AN - SCOPUS:85072059129
SN - 1040-8444
VL - 49
SP - 36
EP - 84
JO - Critical reviews in toxicology
JF - Critical reviews in toxicology
IS - 1
ER -